Puma Biotechnology, Inc. (PBYI)
8.26
-0.14
(-1.61%)
USD |
NASDAQ |
Nov 10, 10:12
Puma Biotechnology Enterprise Value : 339.92M for Nov. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 09, 2026 | 339.92M |
| November 06, 2026 | 332.51M |
| November 05, 2026 | 410.19M |
| November 04, 2026 | 457.20M |
| November 03, 2026 | 433.18M |
| November 02, 2026 | 431.14M |
| October 30, 2026 | 444.43M |
| October 29, 2026 | 449.54M |
| October 28, 2026 | 453.62M |
| October 27, 2026 | 468.96M |
| October 26, 2026 | 465.38M |
| October 23, 2026 | 474.07M |
| October 22, 2026 | 486.33M |
| October 21, 2026 | 467.93M |
| October 20, 2026 | 460.78M |
| October 19, 2026 | 432.67M |
| October 16, 2026 | 413.25M |
| October 15, 2026 | 448.51M |
| October 14, 2026 | 432.16M |
| October 13, 2026 | 428.07M |
| October 12, 2026 | 436.76M |
| October 09, 2026 | 436.76M |
| October 08, 2026 | 420.41M |
| October 07, 2026 | 412.23M |
| October 06, 2026 | 396.39M |
| Date | Value |
|---|---|
| October 05, 2026 | 405.08M |
| October 02, 2026 | 396.90M |
| October 01, 2026 | 413.76M |
| September 30, 2026 | 418.36M |
| September 29, 2026 | 410.70M |
| September 28, 2026 | 412.74M |
| September 25, 2026 | 410.19M |
| September 24, 2026 | 412.74M |
| September 23, 2026 | 385.15M |
| September 22, 2026 | 412.74M |
| September 21, 2026 | 400.99M |
| September 18, 2026 | 401.50M |
| September 17, 2026 | 397.41M |
| September 16, 2026 | 390.77M |
| September 15, 2026 | 383.61M |
| September 14, 2026 | 377.99M |
| September 11, 2026 | 376.97M |
| September 10, 2026 | 379.53M |
| September 09, 2026 | 373.39M |
| September 08, 2026 | 390.77M |
| September 04, 2026 | 398.94M |
| September 03, 2026 | 391.79M |
| September 02, 2026 | 406.10M |
| September 01, 2026 | 388.72M |
| August 31, 2026 | 376.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Olema Pharmaceuticals, Inc. | 186.24M |
| Anika Therapeutics, Inc. | 176.34M |
| ACADIA Pharmaceuticals, Inc. | 1.946B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Savara, Inc. | 894.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 6.00M |
| Revenue (Quarterly) | 55.10M |
| Total Expenses (Quarterly) | 49.10M |
| EPS Diluted (Quarterly) | 0.113 |
| Gross Profit Margin (Quarterly) | 72.41% |
| Profit Margin (Quarterly) | 10.89% |
| Earnings Yield | 5.52% |
| Operating Earnings Yield | 6.09% |